Inventya has successfully won grants for three of its clients in the medical sector, take a look at the case studies below to learn more:
NEPeSMO
Chronic Obstructive Pulmonary Disease (COPD) presents a significant health and economic challenge in the UK, standing as the second most common lung condition after asthma. With over 1.2 million individuals diagnosed, the disease imposes a considerable £800 million annual cost on the NHS, with advanced stages of COPD requiring nearly tenfold the resources compared to its milder stages. This situation highlights a critical need to shift our focus towards proactive prevention, not merely treatment.
The Client’s Innovative Approach:
NEPeSMO Limited has emerged at the forefront of this challenge, marrying advanced AI analytics with smart digital monitoring. Their flagship innovation, COPDPredict™, exemplifies their forward-thinking ethos by offering continuous and comprehensive monitoring of COPD patients. The platform meticulously tracks patient data, including daily wellness assessments, spirometry readings, and blood test results, to anticipate potential COPD exacerbations. This predictive prowess empowers clinicians to intervene pre-emptively, aiming to curtail exacerbation frequency and diminish the associated hospitalisation risks.
The initiative’s precision was honed through robust clinical trials involving 384 patients across NHS hospitals, enhancing the data-driven accuracy of COPDPredict™.
Reflective Pride:
NEPeSMO stands as a testament to the transformative power of R&D coupled with seeking support with financing mechanisms and opportunities open to them. At Inventya, we take immense pride in partnering with companies like NEPeSMO and are humbled by their kind words of acknowledgement.
Client Quote:
“Inventya have been excellent in helping to support NEPeSMO both through external funding and tax credits.”– Neil Patel, NEPESMO
ReNewVax
ReNewVax are an innovative company, with a new and novel approach to vaccine development with huge growth potential. However, for startups like ReNewVax, validating hypotheses and building a solid value proposition are critical yet challenging milestones. The quest for private investment is largely supported by evidence of public funding, which itself serves as a testament to the innovation’s scientific credibility and potential. Understanding this, ReNewVax sought a partner to navigate these complexities.
Client Quote:
“Inventya has played a key role in helping us shape our value proposition towards our grant funding applications. They aligned their availability to our deadlines, responded to our queries in a very efficient manner, flagged up relevant funding opportunities, while never overpromising, and always delivering. I highly recommend working with Inventya, a great partner in your growth journey.”– Marie Yang O’Brien, ReNewVax
Afon Technology
Afon’s Challenges:
- Innovative product requiring funding to proceed with development
Established team, but lack of in-house resources for grant writing/application preparation. - Required practice and preparation for EIC Panel interview
Inventya’s Impact:
We helped secure €2.4 million in the EIC Accelerator Competition: Our grant writers crafted a compelling grant proposal, highlighting the innovation of Glucowear®
We conducted focussed Interview Prep: We held targeted interview practice sessions, incorporating a panel of Inventya’s experts across our services, This helped to fine-tune Afon’s pitch and ensure their team was prepared to address potential questions and concerns from the EIC panel.
Client Quote:
“We would like to give special thanks to innovation and commercialisation grant agents Inventya who helped us throughout the application process and interview stage”– Sabih Chaudhry, CEO of Afon Technology
Case studies provided by Inventya, click here to learn more.
